IART

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. About Integra LifeSciences Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com. Investor Relations:Chris Ward(609) [email protected] Media Contact:Laurene Isip(609) [email protected] Integra LifeSciences Holdings Corporation

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Integra LifeSciences (NASDAQ:IART) and the rest of the surgical equipment & consumables - specialty stocks fared in Q1. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 2.7% while next quarter’s revenue guidance was 1.1% below. Thankfully, share prices of the companies have been resilient as they are up 8.1% on average since the latest earnings results. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Integra LifeSciences reported revenues of $391.9 million, up 2.4% year on year. This print exceeded analysts’ expectations by 2.6%. Overall, it was a strong quarter for the company with an impressive beat of analysts’ full-year EPS guidance estimates. “Our first-quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold,” said Stuart Essig, chairman and chief...

It has been about a month since the last earnings report for Integra LifeSciences (IART). Shares have added about 15% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Integra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 54 cents for the first quarter of 2026, which beat the Zacks Consensus Estimate by 32.8%. The metric increased 31.7% year over year. GAAP loss per share was 6 cents in the quarter compared with the year-ago period’s loss of 33 cents. Total revenues in the first quarter rose 2.4% year over year to $391.9 million. The metric topped the Zacks Consensus Estimate by 2.7%. Organically, revenues rose 1.3% year over year. For full-year 2026, the company expects revenues to be in the range of $1.66-$1.70 billion, representing reported growth of 1.6% to 4.1%. The Zacks Consensus Estimate is pegged at $1.67 billion, indicating 2.2% year-over-year growth. Meanwhile, the company updated its expected adjusted EPS to a range of $2.40-$2.50. The Zacks Consensus Estimate for the metric is pegged at $2.42 per share. For the second quarter of 2026, Integra expects reported revenues in the range of $410-$425 million. The Zacks Consensus Estimate is pegged at $417.5 million. Adjusted EPS is expected to be in the range of 44-52 cents. The Zacks Consensus Estimate for the metric is pegged at 49 cents per share. In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -10.74% due to these changes. Currently, Integra has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of B on the value side, putting it in the top 40% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Integra has a Zacks Rank #2 (Buy). We expect an above average return from the stock i...

Integra LifeSciences delivered a first quarter that surpassed Wall Street expectations, as reflected by a significant positive market reaction. Management attributed the results to stronger demand for tissue reconstruction products, improved supply execution, and ongoing transformation initiatives. CEO Stuart Essig, newly reinstated, emphasized that foundational work in quality remediation and operational improvements enabled more reliable product availability. CFO Lea Knight highlighted that increased gross margins were “driven by a favorable product mix, tariff benefits, and reduced remediation costs,” indicating that operational discipline and targeted initiatives were key contributors to the quarter’s performance. Is now the time to buy IART? Find out in our full research report (it’s free). Revenue: $391.9 million vs analyst estimates of $381.9 million (2.4% year-on-year growth, 2.6% beat) Adjusted EPS: $0.54 vs analyst estimates of $0.40 (33.4% beat) Adjusted EBITDA: $76.18 million vs analyst estimates of $66.65 million (19.4% margin, 14.3% beat) The company reconfirmed its revenue guidance for the full year of $1.68 billion at the midpoint Management raised its full-year Adjusted EPS guidance to $2.45 at the midpoint, a 4.3% increase Operating Margin: 10.4%, up from 8.2% in the same quarter last year Organic Revenue rose 1.3% year on year (beat) Market Capitalization: $1.09 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Matthew Taylor (Jefferies) asked why now was the right time for the CEO transition and how future execution would differ. CEO Stuart Essig stressed continuity of strategic initiatives and a renewed commercial focus. Jayson Bedford (Raymond James & Associates) questioned the status of the Compliance Master Plan and product availability. CFO Lea Knight explained that remediation is progressing, and supply improvements have already enhanced Q1 execution, but no major product returns are assumed in guidance. Ryan Zimmerman (BTIG) inquired about portfolio optimization and market focus. Essig stated there are no plans for divestitures or market exits, emphasizing confidence in the current p...

Chairman Stuart Essig has returned to the CEO role to strengthen organizational culture and increase commercial focus following a mutual decision for the prior CEO to step down. The company created a new Chief Commercial Officer role to elevate the commercial organization's voice and ensure customer-facing priorities are represented at the leadership level. First quarter performance exceeded expectations due to solid product demand, improving supply execution, and the positive impact of business transformation activities. Management is prioritizing 'going on the offense' commercially as product availability improves, leveraging strong hospital relationships in the Specialty Surgery segment to drive Tissue Reconstruction growth. The Compliance Master Plan is progressing well, with site assessments completed and remediation work translating into more consistent and predictable supply reliability. Strategic focus remains on niche markets where Integra can maintain top-three positions, specifically in neurosurgery, ENT, and surgical wound care. Full-year 2026 revenue guidance is maintained at $1.66 billion to $1.7 billion, assuming sequential growth driven by seasonality and improved supply reliability. Adjusted EPS guidance was raised by $0.10 to a range of $2.40 to $2.50, exclusively reflecting favorable tariff outcomes realized in the first quarter. Production at the Braintree facility is expected to commence by the end of June, supporting the planned relaunch of SurgiMend by late 2024. Management anticipates PMA approvals for SurgiMend and DuraSorb in 2027, targeting the $800 million implant-based breast reconstruction market. The company aims to reduce its consolidated total leverage ratio from 4.1x to the target range of 2.5 to 3.5x by the end of 2026 through debt paydown and EBITDA growth. A $0.02 net tariff benefit was recorded in Q1 due to an anticipated IEPA refund, contributing to the overall $0.10 tariff-related EPS favorability. CMS changes to Medicare reimbursement for skin substitutes are viewed as a long-term opportunity, as 90% of Integra's revenue is in the unaffected inpatient market. The company renamed its segments to Specialty Surgery (formerly Codman Specialty Surgical) and Tissue Reconstruction (formerly Tissue Technologies) to better reflect their focus. Operating cash flow is expected to increase by approximately $150 million compared t...

Image source: The Motley Fool. May 5, 2026, 8:30 a.m. ET President, Chief Executive Officer, and Chairman — Stuart Essig Executive Vice President and Chief Financial Officer — Lea Knight Stuart Essig: Thank you, Chris. Before we turn to the quarter, I want to address the leadership change that we announced this morning. As you have seen from our announcement, I have stepped back into the role as President and CEO and will retain my current role as Chairman. I want to thank Mojdeh Poul for her leadership and for the meaningful progress made during her tenure. Under her leadership, the company advanced a number of important initiatives, including enterprise-wide portfolio and program prioritization, risk-based approach to quality remediation work, operations resiliency improvements and the more recent transformation and business process optimization efforts. Those efforts matter, and they are progressing well, and we remain fully committed to them. As I step back into the CEO role, my focus will be on strengthening the culture of the organization while increasing our customer and commercial focus. We want to be more connected to our customers, more aligned with the field, more collaborative across functions and clearer and faster in our execution. We are building on the important work already underway while improving how we work together and how quickly we make things happen. We remain committed to the quality, compliance, capacity and transformation work underway across the company. That work is progressing well and remains central to how we improve performance and build a stronger Integra. As we also announced this morning, Mike McBreen has been appointed Chief Commercial Officer. Some of you already know Mike well. He is exceptionally well suited for this role with more than 30 years of commercial experience in the medical technology industry. This newly created role is an important part of how we move forward, and Mike will help drive the next phase of our commercial organization. This move reflects the importance we place on making sure the commercial organization has a strong voice at the leadership table and that customer and market-facing priorities are fully represented in how we operate and make decisions. This is not about changing direction in the commercial organization. It is about raising its profile, strengthening leadership support around it a...

Q1 beat and guidance change: Integra reported Q1 revenue of $392 million and adjusted EPS of $0.54, both above the high end of guidance, and raised full-year adjusted EPS to $2.40–$2.50 after a favorable tariff (IEEPA) outcome that added roughly $0.02 in Q1. Leadership shift and commercial emphasis: Chairman Stuart Essig has resumed the role of President & CEO, and the company appointed Mike McBreen as its first Chief Commercial Officer to raise the profile and coordination of market-facing functions. Segment performance and financial outlook: Tissue Reconstruction grew about 6% organically while Specialty Surgery was down ~0.6% organic, management kept full-year revenue guidance at $1.66–$1.70 billion and expects margin improvement and progress toward reducing leverage toward its 2.5–3.5x target. Interested in Integra LifeSciences Holdings Corporation? Here are five stocks we like better. 3 Undervalued Midcaps Ready to Pop Integra LifeSciences (NASDAQ:IART) reported first-quarter 2026 results that exceeded the high end of management’s guidance ranges, while also outlining leadership changes and reiterating its full-year revenue outlook. Chairman Stuart Essig said he has “stepped back into the role as President and CEO” and will retain his role as Chairman. Essig thanked outgoing CEO Mojdeh Poul and credited her with advancing initiatives including “enterprise-wide portfolio and program prioritization,” a “risk-based approach to quality remediation work,” and “operations resiliency improvements,” along with transformation and business process optimization efforts. → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Essig told analysts the decision for Poul to step down “was mutual between her and the board,” adding that while there were “differences in certain strategic topics,” transformation initiatives put in place will continue unchanged. As part of organizational changes, Essig announced the appointment of Mike McBreen as the company’s first Chief Commercial Officer, calling the role an effort to elevate commercial priorities at the leadership level. Essig said the change is “not about changing direction in the commercial organization,” but about “raising its profile” and improving coordination across market-facing functions. When asked whether the company would expand the sales force, Essig said the move does not imply higher or lower s...

PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026. First Quarter 2026 Highlights First quarter revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.06), compared to $(0.33) in the prior year. Adjusted earnings per diluted share of $0.54, compared to $0.41 in the prior year. Reaffirming 2026 full year revenue guidance of $1.662 billion to $1.702 billion and updating 2026 adjusted earnings per share guidance from a range of $2.30 to $2.40 to a range of $2.40 to $2.50. As noted in a separate press release issued this morning, Stuart Essig has been appointed as Integra’s next President and Chief Executive Officer and Michael McBreen has been promoted to Chief Commercial Officer. “Our first-quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold,” said Stuart Essig, chairman and chief executive officer. “During the quarter, we continued to drive improved supply reliability, supporting strong growth in Integra Skin and our return to market with PriMatrix® and Durepair®. We made meaningful progress at our state-of-the-art Braintree manufacturing facility and remain on track to begin production of SurgiMend® by the end of June to support a fourth quarter launch. Building on these efforts, we are focused on maintaining disciplined execution and remain confident in our ability to deliver our full-year commitments to our customers, patients, and shareholders." First Quarter 2026 Consolidated Performance Total reported revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 55.4%, compared to 50.8% in the first quarter of 2025. Adjusted gross margin was 64.1%, compared to 62.2% in the prior year. Adjusted EBITDA for the first quarter of 2026 was $76.2 million, or 19.4% of revenue, compared to $63.6 million, or 16.6% of revenue, in the prior year. The Company reported a GAAP net loss of $(4.6) million, or $(0.06) per...

Integra LifeSciences Holdings (IART) shares were up past 21% in early trading on Tuesday after the c

For the quarter ended March 2026, Integra LifeSciences (IART) reported revenue of $391.92 million, up 2.4% over the same period last year. EPS came in at $0.54, compared to $0.41 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $381.46 million, representing a surprise of +2.74%. The company delivered an EPS surprise of +32.78%, with the consensus EPS estimate being $0.41. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Organic Revenue Growth: 1.3% versus -1.9% estimated by two analysts on average. Revenue- Tissue Technologies- Wound Reconstruction and Care: $79.65 million versus $70.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.5% change. Revenue- Tissue Technologies- Total: $108.78 million versus the two-analyst average estimate of $99.48 million. The reported number represents a year-over-year change of +6.7%. Revenue- Codman Specialty Surgical- Total: $283.14 million versus $281.62 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +0.9% change. Revenue- Tissue Technologies- Private Label: $29.14 million compared to the $28 million average estimate based on two analysts. The reported number represents a change of +7.1% year over year. View all Key Company Metrics for Integra here>>> Shares of Integra have returned +14.4% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integra LifeSciences Holdings Corporat...

Integra LifeSciences (IART) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +32.78%. A quarter ago, it was expected that this medical device maker would post earnings of $0.79 per share when it actually produced earnings of $0.83, delivering a surprise of +5.06%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Integra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $391.92 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.74%. This compares to year-ago revenues of $382.65 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Integra shares have lost about 14.3% since the beginning of the year versus the S&P 500's gain of 5.2%. While Integra has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Integra was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Str...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Integra LifeSciences Holdings Corp. (IART) on Tuesday reported a loss of $4.6 million in its first quarter. On a per-share basis, the Princeton, New Jersey-based company said it had a loss of 6 cents. Earnings, adjusted for non-recurring costs, came to 54 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 41 cents per share. The medical device maker posted revenue of $391.9 million in the period, also topping Street forecasts. Three analysts surveyed by Zacks expected $381.5 million. Integra expects full-year earnings in the range of $2.40 to $2.50 per share, with revenue in the range of $1.66 billion to $1.7 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IART at https://www.zacks.com/ap/IART